Prevalence of human papillomavirus genotypes and relative risk of cervical cancer in China: a systematic review and meta-analysis
- PMID:29632652
- PMCID: PMC5880612
- DOI: 10.18632/oncotarget.24169
Prevalence of human papillomavirus genotypes and relative risk of cervical cancer in China: a systematic review and meta-analysis
Abstract
High-risk HPV (hrHPV) is related to cervical carcinogenesis, although clinical data comparing the natural history and carcinogenic potential of type-specific HPV remain limited. Furthermore, the nationwide prevalence rates of overall and type-specific HPV among women with cervical precancerous lesions and cancer have not been reported. Here, a meta-analysis was performed for type-specific HPV distribution among 30,165 HPV-positive women, including 12,094 invasive cervical cancers (ICCs), 10,026 cervical intraepithelial neoplasia grade 2/3 (CIN2/3), 3246 CIN1, and 4799 normal cervices from 45 PCR-based studies. We found that HPV16 was the most common hrHPV type involved in cervical disease. The HPV16 positivity rate varied little across normal (22.7%) and CIN1 individuals (23.6%) but increased through the CIN2 (37.6%) and CIN3 patients (51.9%) to 65.6% in ICC cases. HPV16, 18, 35, 39, 45, and 59 were more frequent in ICC than CIN3, with ICC:CIN3 ratios ranging from 2.3 for HPV18 to 1.1 for HPV35/45. HPV31, 33, 52, and 58 were more frequent in CIN3 compared with normal cervices but less common in ICC compared with CIN3 (ICC:CIN3 ratios ranging from 0.6 for HPV58 and 0.4 for HPV52). The ICC:normal ratios were particularly high for HPV18, 52 and 58 in West China (4.1, 3.9 and 2.9, respectively) and for HPV45 and 59 in North China (1.6 and 1.1, respectively). In summary, this study is the most comprehensive analysis of type-specific HPV distribution in cervical carcinogenesis and could be valuable for HPV-based cervical cancer screening strategies and vaccination policies in China.
Keywords: cervical cancer; cervical precancerous lesion; genotype; human papillomavirus; meta-analysis.
Conflict of interest statement
CONFLICTS OF INTEREST The authors declare that they have no competing interests.
Figures
Similar articles
- Ranking the attribution of high-risk genotypes among women with cervical precancers and cancers: a cross-sectional study in Ningbo, China.Chen S, Hu S, Yin J, Yu W, Zhang X, Deng X, Ding H, Zhang J, Song Y, Wang Q, Chen L, Guo F, Hartwig S, Zhao F.Chen S, et al.Infect Agent Cancer. 2024 Sep 12;19(1):43. doi: 10.1186/s13027-024-00598-z.Infect Agent Cancer. 2024.PMID:39267045Free PMC article.
- Distribution of high-risk human papillomavirus genotype prevalence and attribution to cervical precancerous lesions in rural North China.Zhao S, Zhao X, Hu S, Lu J, Duan X, Zhang X, Chen F, Zhao F.Zhao S, et al.Chin J Cancer Res. 2019 Aug;31(4):663-672. doi: 10.21147/j.issn.1000-9604.2019.04.10.Chin J Cancer Res. 2019.PMID:31564809Free PMC article.
- Human papillomavirus infections among Japanese women: age-related prevalence and type-specific risk for cervical cancer.Onuki M, Matsumoto K, Satoh T, Oki A, Okada S, Minaguchi T, Ochi H, Nakao S, Someya K, Yamada N, Hamada H, Yoshikawa H.Onuki M, et al.Cancer Sci. 2009 Jul;100(7):1312-6. doi: 10.1111/j.1349-7006.2009.01161.x. Epub 2009 Apr 22.Cancer Sci. 2009.PMID:19432906Free PMC article.
- Fluorescence In Situ Hybridization (FISH) or Other In Situ Hybridization (ISH) Testing of Uterine Cervical Cells to Predict Precancer and Cancer [Internet].Uhlig K, Earley A, Lamont J, Dahabreh IJ, Avendano EE, Cowan JM, Feldman S.Uhlig K, et al.Rockville (MD): Agency for Healthcare Research and Quality (US); 2013 Feb 16.Rockville (MD): Agency for Healthcare Research and Quality (US); 2013 Feb 16.PMID:25855849Free Books & Documents.Review.
- Evidence regarding human papillomavirus testing in secondary prevention of cervical cancer.Arbyn M, Ronco G, Anttila A, Meijer CJ, Poljak M, Ogilvie G, Koliopoulos G, Naucler P, Sankaranarayanan R, Peto J.Arbyn M, et al.Vaccine. 2012 Nov 20;30 Suppl 5:F88-99. doi: 10.1016/j.vaccine.2012.06.095.Vaccine. 2012.PMID:23199969Review.
Cited by
- Prevalence and genotype distribution of HPV combined with cervical pathological results in women from Sichuan, China: A cross-sectional study based on post-vaccination period 2019 to 2023.Mo B, Ye Y, Yu M, Tong X, Cao H, Du C, Luo J, Xie C.Mo B, et al.Cancer Med. 2024 Aug;13(16):e70148. doi: 10.1002/cam4.70148.Cancer Med. 2024.PMID:39189602Free PMC article.
- Diagnostic value of high-risk HPV other than type 16/18 in high-grade cervical neoplasia among cytology-negative women: A multicenter retrospective study.Bai A, Xue P, Li Q, Jiang Y, Qiao Y.Bai A, et al.Cancer Med. 2023 Jul;12(13):14794-14805. doi: 10.1002/cam4.6109. Epub 2023 May 18.Cancer Med. 2023.PMID:37199394Free PMC article.
- Current Updates on Cancer-Causing Types of Human Papillomaviruses (HPVs) in East, Southeast, and South Asia.Xia C, Li S, Long T, Chen Z, Chan PKS, Boon SS.Xia C, et al.Cancers (Basel). 2021 May 30;13(11):2691. doi: 10.3390/cancers13112691.Cancers (Basel). 2021.PMID:34070706Free PMC article.Review.
- Current issues facing the introduction of human papillomavirus vaccine in China and future prospects.Wong LP, Han L, Li H, Zhao J, Zhao Q, Zimet GD.Wong LP, et al.Hum Vaccin Immunother. 2019;15(7-8):1533-1540. doi: 10.1080/21645515.2019.1611157. Epub 2019 Jul 16.Hum Vaccin Immunother. 2019.PMID:31017500Free PMC article.Review.
- Cervical cancer: a meta-analysis, therapy and future of nanomedicine.Venkatas J, Singh M.Venkatas J, et al.Ecancermedicalscience. 2020 Sep 24;14:1111. doi: 10.3332/ecancer.2020.1111. eCollection 2020.Ecancermedicalscience. 2020.PMID:33144879Free PMC article.Review.
References
- Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray F, Jemal A, Yu XQ, He J. Cancer statistics in China, 2015. CA Cancer J Clin. 2016;66:115–32. - PubMed
- Crosbie EJ, Einstein MH, Franceschi S, Kitchener HC. Human papillomavirus and cervical cancer. Lancet. 2013;382:889–99. - PubMed
- Muñoz N, Bosch FX, de Sanjosé S, Herrero R, Castellsagué X, Shah KV, Snijders PJ, Meijer CJ, International Agency for Research on Cancer Multicenter Cervical Cancer Study Group Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med. 2003;348:518–27. - PubMed
- Cogliano V, Baan R, Straif K, Grosse Y, Secretan B, El Ghissassi F, WHO International Agency for Research on Cancer Carcinogenicity of human papillomaviruses. Lancet Oncol. 2005;6:204. - PubMed
- Ronco G, Dillner J, Elfström KM, Tunesi S, Snijders PJ, Arbyn M, Kitchener H, Segnan N, Gilham C, Giorgi-Rossi P, Berkhof J, Peto J, Meijer CJ, International HPV screening working group Efficacy of HPV-based screening for prevention of invasive cervical cancer: follow-up of four European randomized controlled trials. Lancet. 2014;383:524–32. - PubMed
Related information
LinkOut - more resources
Full Text Sources
Other Literature Sources